

Successful recanalization was defined as restoration of antegrade iliac venous flow after angioplasty alone or angioplasty and placement of additional stents.

**Results:** Percutaneous recanalization of chronically occluded iliac venous stents using the PowerWire was successful in 10 patients. Cumulative 6-month patency rate was 62%. Cumulative 12-month patency rate was 43%. There were two complications that occurred with use of the PowerWire. One patient had transient footdrop of the ipsilateral limb that was successfully recanalized. One patient had self-limited perforation of the left common iliac artery during unsuccessful recanalization.

**Conclusions:** The PowerWire is an effective and relatively safe device for recanalizing chronically occluded iliac venous stents.

**Author Disclosures:** N. Neidert: Nothing to disclose; H. Bjarnason: Nothing to disclose.

### Impact of Presence of Inferior Vena Cava Filter on Iliocaval Stent Outcomes



Arjun Jayaraj, Laura Lamanilao, Seshadri Raju. RANE Center for Venous and Lymphatic Disease at St. Dominic Hospital

**Objective:** The impact of presence of an inferior vena cava (IVC) filter in patients undergoing stenting for symptomatic femoroiliocaval obstruction has not been explored in detail. This study attempted to fill this gap by evaluating clinical and stent-related outcomes in such patients. The incidence of deep venous thrombosis (DVT) in this setting was also analyzed.

**Methods:** A retrospective review of contemporaneously entered electronic medical record data on initial iliocaval stents placed in patients with an indwelling IVC filter (or placed after stenting) during a 15-year period from 2000 to 2015 was performed. A separate cohort that underwent initial stenting during the time frame but that did not have an IVC filter was used as the control group. Clinical outcomes were evaluated through use of the Venous Clinical Severity Score (VCSS). The incidence of DVT was reviewed in both groups. Kaplan-Meier analysis was used to assess stent patency after intervention, whereas paired *t*-test was used to examine preintervention and postintervention outcomes within and between groups.

**Results:** A total of 57 patients underwent placement of a femoroiliocaval stent in the setting of a pre-existing (46) or post-stent (11) IVC filter (filter group). The control group had 359 patients. There was no difference in VCSS at baseline between the two groups. During a median follow-up of 59 months, VCSS went from 5 to 2 at 12 months ( $P = .84$ ) in the filter group and from 5 to 3.5 in the control group ( $P < .01$ ). However, there was no statistically significant difference in the VCSS between the two groups at 12 months ( $P = .09$ ). The incidence of ipsilateral DVT in the filter group was 7%, and that in the treatment group was 3% ( $P = .10$ ). There were no contralateral DVTs in either group. Median primary, primary assisted, and secondary patencies in the filter/control groups were 116/64 ( $P < .01$ ), 137/58 ( $P < .01$ ), and 29/30 months ( $P = .77$ ).

**Conclusions:** Presence of an IVC filter does not appear to affect clinical outcomes after femoroiliocaval stenting. However, counterintuitively, they appear to confer better primary and primary assisted stent patencies.

**Author Disclosures:** A. Jayaraj: Nothing to disclose; L. Lamanilao: Nothing to disclose; S. Raju: Nothing to disclose.

### Improvement in Quality of Life After Iliac Vein Stenting in a Prospective Clinical Study of a Nitinol Venous Stent



William Marston,<sup>1</sup> Mahmood Razavi,<sup>2</sup> <sup>1</sup>University of North Carolina School of Medicine; <sup>2</sup>St. Joseph's Hospital, Orange, Calif

**Objective:** Stenting of the iliofemoral venous outflow tract is recommended to treat patients with significant limb symptoms related to obstruction. However, it remains unclear which patients benefit most from iliac vein stenting. In this prospective clinical trial studying the

performance of a nitinol stent designed for the treatment of venous obstructive disease, quality of life (QOL) measures were related to patient and procedural characteristics to determine which patients benefit most from venous stenting.

**Methods:** There were 170 patients with chronic iliofemoral venous obstruction enrolled in a prospective pivotal trial studying the effectiveness of a nitinol venous stent (Veniti, Inc, Fremont, Calif). Before intervention, QOL was measured with the Venous Clinical Severity Score (VCSS) and Chronic Venous Insufficiency Questionnaire (CIVIQ-2) score. Venography was performed, and the presence of vessel stenosis of >50% was required for study inclusion. Intravascular ultrasound (IVUS) was also performed before and after stent insertion to allow calculation of lumen diameter and area. QOL was measured with VCSS and CIVIQ-2 at 1 month, 6 months, and 12 months after stenting, and repeated venography and IVUS were performed at 12 months.

**Results:** Of the cohort, 140 had QOL measures performed before stenting and at 12 months of follow-up. Of these, 133 had IVUS measurements at the time of stent insertion and 94 had IVUS at 12 months. Both VCSS and CIVIQ-2 score improved significantly at 1 month and 12 months after stenting as noted in the Table. Improvement in VCSS was similar in patients treated for nonthrombotic ( $5.2 \pm 5.6$  points) and post-thrombotic ( $4.0 \pm 3.9$  points) disease. Patients who experienced significant improvement in VCSS ( $\geq 3$  points;  $n = 91$ ) had a significantly higher mean maximal area stenosis on IVUS before stenting ( $70.1\% \pm 20\%$ ) than 32 patients who had <2 points of improvement on VCSS ( $57.2\% \pm 25.9\%$ ;  $P = .007$ ). VCSS improvement at 12 months did not correlate with the maximal percentage diameter or percentage area stenosis on IVUS at 12 months.

**Conclusions:** The majority of patients treated with venous stenting for symptomatic iliofemoral venous obstruction experience significant reduction in symptoms that is durable to 12 months of follow-up. QOL improvement was significantly more frequent in patients stented for more severe venous obstruction.

**Author Disclosures:** W. Marston: honorarium Veniti; M. Razavi: Honorarium Veniti, Boston Scientific.

### Relevance of Thrombophilia Testing in Patients Undergoing Iliofemoral Venous Stenting for Post-Thrombotic Occlusion



Laura Tinnckell,<sup>1</sup> Adam Gwozdz,<sup>1</sup> Nicholas Jackson,<sup>1</sup> Justinas Silickas,<sup>1</sup> Alberto Smith,<sup>1</sup> Prakash Saha,<sup>1</sup> Karen Breen,<sup>2</sup> Stephen Black.<sup>1</sup> <sup>1</sup>Academic Department of Vascular Surgery, School of Cardiovascular Medicine and Science, St Thomas' Hospital, King's College London; <sup>2</sup>Department of Haematology, St Thomas' Hospital, King's College London

**Objective:** Inherited and acquired thrombophilias increase the risk of venous thromboembolism (VTE), and the antiphospholipid antibody syndrome (APS), an acquired thrombophilia, is associated with a high risk of recurrent VTE. Postoperative anticoagulation therapies remain tailored, with APS patients requiring long-term vitamin K antagonists (VKAs) compared with direct oral anticoagulants for patients with inherited thrombophilia. As such, iliofemoral venous stenting in patients with thrombophilia is controversial. The aim of this study was to examine the association of thrombophilia with cumulative patency and reintervention rates after stenting for post-thrombotic occlusion.

**Methods:** Consecutive patients (2012-2017) receiving a nitinol venous stent for post-thrombotic disease with a minimum of 1-year follow-up were included for analysis. Thrombophilia testing was performed when VTE occurred at a young age with weak provoking factors, strong family history, or recurrence. Patients with strong risk factors for VTE were not tested and were excluded from analysis. All patients were given therapeutic dose low-molecular-weight heparin divided twice daily for 2 weeks after the procedure, followed by a VKA for 6 months. Patients with APS continued on long-term VKA therapy at 6 months, whereas all other patients were transitioned to direct oral anticoagulants. Stent

**Table.** Venous Clinical Severity Score (VCSS) and Chronic Venous Insufficiency Questionnaire (CIVIQ-2) score at 1 month and 12 months

	Before stenting	1 month after stenting	12 months after stenting	<i>P</i> value before vs 1 month	<i>P</i> value before vs 12 months
VCSS	9.9 ± 5.0	6.3 ± 4.3	5.7 ± 4.3	<.00001	<.000001
CIVIQ-2	0.44 ± 0.24	0.30 ± 0.25	0.27 ± 0.25	<.00001	<.00001